Literature DB >> 17869367

Liberation of doxorubicin from HPMA copolymer conjugate is essential for the induction of cell cycle arrest and nuclear fragmentation in ovarian carcinoma cells.

A Malugin1, P Kopecková, J Kopecek.   

Abstract

Despite intensive study, the molecular mechanism for cell toxicity of N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound doxorubicin remains unclear. Moreover, the ability of the released drug to accumulate in the nucleus has also been questioned. We have hypothesized that the pattern of cell cycle progression is a useful indicator for the presence of free doxorubicin in the nucleus and its interaction with nuclear DNA. The effects of HPMA copolymer-bound doxorubicin on cell cycle progression were evaluated in this study in cultured human ovarian cancer A2780 cells. We determined that P-GFLG-DOX, but not P-GG-DOX, initiates cell cycle arrest and nuclear fragmentation in the same manner as free DOX, but with a time-delay. Our data indicate that drug release from the conjugate is required for the apoptotic activity associated with the conjugate.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17869367      PMCID: PMC2175206          DOI: 10.1016/j.jconrel.2007.08.016

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  23 in total

1.  Soluble biomedical polymers.

Authors:  J Kopecek
Journal:  Polim Med       Date:  1977

2.  Preliminary evaluation of caspases-dependent apoptosis signaling pathways of free and HPMA copolymer-bound doxorubicin in human ovarian carcinoma cells.

Authors:  T Minko; P Kopecková; J Kopecek
Journal:  J Control Release       Date:  2001-04-28       Impact factor: 9.776

3.  The same drug but a different mechanism of action: comparison of free doxorubicin with two different N-(2-hydroxypropyl)methacrylamide copolymer-bound doxorubicin conjugates in EL-4 cancer cell line.

Authors:  Lubomír Kovár; Jirí Strohalm; Petr Chytil; Tomás Mrkvan; Marek Kovár; Ondrej Hovorka; Karel Ulbrich; Blanka Ríhová
Journal:  Bioconjug Chem       Date:  2007-04-03       Impact factor: 4.774

4.  HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 1. influence of the method of synthesis on the binding affinity to OVCAR-3 ovarian carcinoma cells in vitro.

Authors:  V Omelyanenko; P Kopecková; C Gentry; J G Shiah; J Kopecek
Journal:  J Drug Target       Date:  1996       Impact factor: 5.121

5.  Time- and concentration-dependent apoptosis and necrosis induced by free and HPMA copolymer-bound doxorubicin in human ovarian carcinoma cells.

Authors:  M Demoy; T Minko; P Kopecková; J Kopecek
Journal:  J Control Release       Date:  2000-10-03       Impact factor: 9.776

6.  Differences in the intracellular fate of free and polymer-bound doxorubicin.

Authors:  Ondrej Hovorka; M St'astný; T Etrych; V Subr; J Strohalm; K Ulbrich; B Ríhová
Journal:  J Control Release       Date:  2002-04-23       Impact factor: 9.776

7.  HPMA copolymer-bound doxorubicin induces apoptosis in human ovarian carcinoma cells by a Fas-independent pathway.

Authors:  Alexander Malugin; Pavla Kopecková; Jindrich Kopecek
Journal:  Mol Pharm       Date:  2004 May-Jun       Impact factor: 4.939

8.  Cell surface-directed interaction of anthracyclines leads to cytotoxicity and nuclear factor kappaB activation but not apoptosis signaling.

Authors:  N Maestre; T R Tritton; G Laurent; J P Jaffrézou
Journal:  Cancer Res       Date:  2001-03-15       Impact factor: 12.701

9.  HPMA copolymers containing doxorubicin bound by a proteolytically or hydrolytically cleavable bond: comparison of biological properties in vitro.

Authors:  M Kovár; L Kovár; V Subr; T Etrych; K Ulbrich; T Mrkvan; J Loucká; B Ríhová
Journal:  J Control Release       Date:  2004-09-30       Impact factor: 9.776

10.  Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate.

Authors:  V Omelyanenko; P Kopecková; C Gentry; J Kopecek
Journal:  J Control Release       Date:  1998-04-30       Impact factor: 9.776

View more
  15 in total

1.  Targeting of multidrug-resistant human ovarian carcinoma cells with anti-P-glycoprotein antibody conjugates.

Authors:  Kirk D Fowers; Jindřich Kopeček
Journal:  Macromol Biosci       Date:  2012-01-25       Impact factor: 4.979

2.  Polymeric conjugates for drug delivery.

Authors:  Nate Larson; Hamidreza Ghandehari
Journal:  Chem Mater       Date:  2012-01-04       Impact factor: 9.811

3.  Targeted albumin-based nanoparticles for delivery of amphipathic drugs.

Authors:  Rongzuo Xu; Michael Fisher; R L Juliano
Journal:  Bioconjug Chem       Date:  2011-04-19       Impact factor: 4.774

4.  Advanced architectures in the design of responsive polymers for cancer nanomedicine.

Authors:  Angela M Wagner; Nicholas A Peppas; David S Spencer
Journal:  J Appl Polym Sci       Date:  2018-01-31       Impact factor: 3.125

5.  HPMA copolymer-aminohexylgeldanamycin conjugates targeting cell surface expressed GRP78 in prostate cancer.

Authors:  Nate Larson; Abhijit Ray; Alexander Malugin; Daniel B Pike; Hamidreza Ghandehari
Journal:  Pharm Res       Date:  2010-09-16       Impact factor: 4.200

6.  PEGylated PAMAM dendrimer-doxorubicin conjugates: in vitro evaluation and in vivo tumor accumulation.

Authors:  Saijie Zhu; Minghuang Hong; Lihong Zhang; Guotao Tang; Yanyan Jiang; Yuanying Pei
Journal:  Pharm Res       Date:  2009-10-28       Impact factor: 4.200

7.  Cellular uptake and internalization of hyaluronan-based doxorubicin and cisplatin conjugates.

Authors:  Shuang Cai; Adel Ali B Alhowyan; Qiuhong Yang; W C Melanie Forrest; Yelizaveta Shnayder; M Laird Forrest
Journal:  J Drug Target       Date:  2014-06-03       Impact factor: 5.121

8.  HPMA copolymers: origins, early developments, present, and future.

Authors:  Jindrich Kopecek; Pavla Kopecková
Journal:  Adv Drug Deliv Rev       Date:  2009-11-14       Impact factor: 15.470

9.  Protease-activated drug development.

Authors:  Ki Young Choi; Magdalena Swierczewska; Seulki Lee; Xiaoyuan Chen
Journal:  Theranostics       Date:  2012-02-08       Impact factor: 11.556

10.  Synthesis and therapeutic effect of styrene-maleic acid copolymer-conjugated pirarubicin.

Authors:  Kenji Tsukigawa; Long Liao; Hideaki Nakamura; Jun Fang; Khaled Greish; Masaki Otagiri; Hiroshi Maeda
Journal:  Cancer Sci       Date:  2015-02-03       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.